MeiraGTx Holdings plc

General Information
Business:

 

We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

 

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 59
Founded: 2015
Contact Information
Address 430 East 29th Street, 10th Floor, New York, NY 10016, US
Phone Number (646) 490-2965.
Web Address http://www.meiragtx.com
View Prospectus: MeiraGTx Holdings plc
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-42.1 mil (last 12 months)
IPO Profile
Symbol MGTX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers BofA Merrill Lynch/ Barclays/ Evercore ISI
CO-Managers Chardan
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change